Pseudovirus News and Research

RSS

Isolation of potent neutralizing monoclonal antibodies using nanoparticles displaying SARS-CoV-2 S glycoprotein

A new study aimed to identify several potent neutralizing RBD-directed and NTD-directed mAbs that used a nanoparticle displaying the S glycoprotein to capture SARS-CoV-2-specific B cells.

2 Nov 2021

SARS-CoV-2 variants neutralized by camel nanobodies

Researchers from the US recently isolated two VHH nanobodies - 7A3 and 8A2 - from dromedary camels (Camelus dromedaries) using phage display. These nanobodies were found to have a high affinity for the spike RBD and broad neutralization abilities against SARS-CoV-2 and its variants.

2 Nov 2021

Structure of human-infecting canine coronavirus HuPn-2018 spike glycoprotein

As CCoV-HuPn-2018 has been recently isolated in a child's respiratory swab, researchers from the University Of Washington have been examining the structure of the virus.

28 Oct 2021

Study finds SARS-CoV-2 infection is proportional to cell surface ACE2 levels

Researchers from Oregon State University have developed a system to assess the ability of SARS-CoV-2 to bind to ACE2 orthologs.

26 Oct 2021

Hydrogel-based vaccine delivery system evokes antibody response against SARS-CoV-2

Researchers from Stanford University have been attempting to create a hydrogel-based vaccine delivery system that could improve the immune response's strength and duration.

22 Oct 2021

SARS-CoV-2 cocktail with three antibodies potent in preclinical testing

Amidst growing concerns on the use and potential benefits of convalescent plasma therapy, a research group in the United States has identified three human antibodies (Abs) that, when combined, demonstrate both robust viral suppressive properties against all tested severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Variants of Concern (VoC) in vitro and profound antiviral efficacy in vivo.

22 Oct 2021

The neutralization potential of nanobodies against SARS-CoV-2

A recent review describes the role of nanobodies as a new class of recombinant antibodies that are used in the treatment of COVID-19.

20 Oct 2021

BNT162b2 mRNA COVID-19 vaccine-induced antibodies wane over six month period

Researchers have been investigating the response of antibodies created against SARS-CoV-2 by the Pfizer-BioNTech six months after vaccination.

20 Oct 2021

Structural mechanism of anti-SARS-CoV-2 neutralizing antibodies that target separate spike epitopes

Researchers from the Washington University School Of Medicine have identified how a subset of variants of concern can escape neutralization by two neutralizing antibodies.

19 Oct 2021

Role of CRISPR-Cas12a visual biosensor in detection of SARS-CoV-2

A new study aimed to develop a novel CRISPR-Cas12a powered visual biosensor for the detection of SARS-CoV-2.

13 Oct 2021

Development of disinfection process based on ozone for highly efficient inactivation of SARS-CoV-2

This study aimed to evaluate the ozone capacity generated within a newly developed disinfection chamber to eradicate SARS-CoV-2 from porous materials and non-porous materials like glass.

12 Oct 2021

The role of inhibiting palmitoylation of the SARS-CoV-2 spike protein on viral infectivity

It is demonstrated that palmitoylation of the first five cysteine residues of the C-terminal domain of the SARS-CoV-2 spike protein facilitates cell entry and the formation of syncytia.

11 Oct 2021

Moderna COVID vaccine booster dose results in immune memory

A recent study presents evidence that a booster dose of the Moderna vaccine can induce a robust memory immune response against COVID-19.

6 Oct 2021

Using a new public antibody to understand SARS-CoV-2 neutralization

SARS-CoV-2 infects host cells by binding to the angiotensin convertase 2 receptor (ACE2) on the cell surface through its trimeric spike (S) protein. SARS-CoV enters host human cells through endosomes, while SARS-CoV-2 enters through the cell surface and endosomes. The present study published in the journal “Cell Reports” aimed to understand the mechanisms of SARS-CoV-2 antibody neutralization to facilitate the development of therapeutic interventions for COVID-19.

4 Oct 2021

Structure of monoclonal antibody that can potently neutralize SARS-CoV-2 and variants of concern

A new preprint deals with the analysis of the monoclonal antibody J08, which was capable of powerful neutralization of the wildtype SARS-CoV-2, and its VOCs.

1 Oct 2021

Comparison of Pfizer, Moderna, J&J, AZ vaccines for neutralization titer, against Delta and other variants

Is one COVID vaccine better than the other? Four current vaccines — Moderna, Pfizer-BioNTech, Johnson & Johnson, and AstraZeneca — are highly effective against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), but a new medRxiv* study suggests the level of protection varies.

30 Sep 2021

Pseudovirus News and Research

Isolation of potent neutralizing monoclonal antibodies using nanoparticles displaying SARS-CoV-2 S glycoprotein

SARS-CoV-2 variants neutralized by camel nanobodies

Structure of human-infecting canine coronavirus HuPn-2018 spike glycoprotein

Study finds SARS-CoV-2 infection is proportional to cell surface ACE2 levels

Hydrogel-based vaccine delivery system evokes antibody response against SARS-CoV-2

SARS-CoV-2 cocktail with three antibodies potent in preclinical testing

The neutralization potential of nanobodies against SARS-CoV-2

BNT162b2 mRNA COVID-19 vaccine-induced antibodies wane over six month period

Structural mechanism of anti-SARS-CoV-2 neutralizing antibodies that target separate spike epitopes

Role of CRISPR-Cas12a visual biosensor in detection of SARS-CoV-2

Development of disinfection process based on ozone for highly efficient inactivation of SARS-CoV-2

The role of inhibiting palmitoylation of the SARS-CoV-2 spike protein on viral infectivity

Moderna COVID vaccine booster dose results in immune memory

Using a new public antibody to understand SARS-CoV-2 neutralization

Structure of monoclonal antibody that can potently neutralize SARS-CoV-2 and variants of concern

Comparison of Pfizer, Moderna, J&J, AZ vaccines for neutralization titer, against Delta and other variants

Quantification of antibody titers against SARS-CoV-2 variants elicited by BNT162b2 vaccine

Chronic COVID-19 and divergent variants of SARS-CoV-2

Trial of Sanofi/GSK SARS-CoV-2 vaccine boosters against variants in non-human primates

SARS-CoV-2 entry inhibitors show antiviral activity

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News